Monoamine oxidase (MAO) is an enzyme responsible for metabolism of monoamine neurotransmitters which plays an important role in the brain development and function. This enzyme exists as two isoforms, and it has been demonstrated that MAO-B activity, but not MAO-A activity, increases with aging. MAO inhibitors show a clinical value because besides the monoamine levels regulation they reduce the formation of by-products of the MAO catalytic cycle, which are toxic in the brain. A series of 2-phenylbenzofuran derivatives was designed, synthesized and evaluated against hMAO-A and hMAO-B enzymes. A bromine substituent was introduced in the 2-phenyl ring, whereas the position 5 or 7 of the benzofuran moiety was substituted with a methyl group. Most of the tested compounds inhibited preferentially MAO-B in a reversible manner, with IC50 values in the low micro or nanomolar range. The 2-(2’-bromophenyl)-5-methylbenzofuran 5 was the most active compound identified (IC50 = 0.20 µM). In addition, none of the studied compounds showed cytotoxic activity against human neuroblastome cell line SH-SY5Y. Molecular docking simulations were used to explain the observed hMAO-B structure-activity relationship for this type of compounds
MAO Inhibitory Activity of Bromo-2-phenylbenzofurans: Synthesis, in vitro Study and Docking Calculations
DELOGU, GIOVANNA LUCIA
;PINTUS, FRANCESCA;
2017-01-01
Abstract
Monoamine oxidase (MAO) is an enzyme responsible for metabolism of monoamine neurotransmitters which plays an important role in the brain development and function. This enzyme exists as two isoforms, and it has been demonstrated that MAO-B activity, but not MAO-A activity, increases with aging. MAO inhibitors show a clinical value because besides the monoamine levels regulation they reduce the formation of by-products of the MAO catalytic cycle, which are toxic in the brain. A series of 2-phenylbenzofuran derivatives was designed, synthesized and evaluated against hMAO-A and hMAO-B enzymes. A bromine substituent was introduced in the 2-phenyl ring, whereas the position 5 or 7 of the benzofuran moiety was substituted with a methyl group. Most of the tested compounds inhibited preferentially MAO-B in a reversible manner, with IC50 values in the low micro or nanomolar range. The 2-(2’-bromophenyl)-5-methylbenzofuran 5 was the most active compound identified (IC50 = 0.20 µM). In addition, none of the studied compounds showed cytotoxic activity against human neuroblastome cell line SH-SY5Y. Molecular docking simulations were used to explain the observed hMAO-B structure-activity relationship for this type of compoundsFile | Dimensione | Formato | |
---|---|---|---|
Delogu et al_2017_MedChemComm.pdf
Solo gestori archivio
Tipologia:
versione editoriale (VoR)
Dimensione
1.69 MB
Formato
Adobe PDF
|
1.69 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.